Eslicarbazepine Acetate

醋酸艾司利卡西平

Report date: 2025/05/21 20:00:31
NME

Base Information

Drug NameEslicarbazepine Acetate
Drug Alias NameEslicarbazepinaEslicarbazepinumZebinixStedesaExelief +[12
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel alpha subunit blockers
TargetsSodium channel alpha subunit
Therapy Area/IndicationsBipolar I DisorderNeuralgia, PostherpeticNeuralgia +[9
Global Approved IndicationsSeizuresEpilepsy
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2009/04/20
Country/TerritoryCzechiaBelgiumBulgaria +[28
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBial-Portela
China Registration ClassN/A

Develop Information

Inactive CompaniesBIAL-Portela & CA SA
Active IndicationsSeizuresEpilepsy
Inactive IndicationsBipolar I DisorderNeuralgia, PostherpeticNeuralgia +[7

Other Information

ATC CodeN03AF04